Patents Examined by Manjunath N. Rao
  • Patent number: 10208323
    Abstract: The present invention relates to a recombinant nucleic acid molecule, a recombinant microorganism, to a method for producing alanine and to the use of the recombinant nucleic acid molecule or the recombinant microorganism for the fermentative production of alanine.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: February 19, 2019
    Assignee: BASF SE
    Inventors: Hartwig Schroeder, Holger Hartmann, Qingzhao Wang, Shakir Siraj Ratani, Zheyuan Guo, Markus Pompejus
  • Patent number: 10202623
    Abstract: An object of the present invention is to provide a series of techniques for producing 1,4-butanediol from methanol or the like. Provided is a recombinant cell prepared by introducing a gene encoding at least one enzyme selected from the group consisting of succinate semialdehyde dehydrogenase, succinyl-CoA synthase, CoA-dependent succinate semialdehyde dehydrogenase, 4-hydroxybutyrate dehydrogenase, 4-hydroxybutyryl-CoA transferase, 4-hydroxybutyryl-CoA reductase, 4-hydroxybutyraldehyde dehydrogenase, and alcohol dehydrogenase, into a host cell which is a methylotroph, wherein the gene is expressed in the host cell, and the recombinant cell is capable of producing 1,4-butanediol from at least one C1 compound selected from the group consisting of methane, methanol, methylamine, formic acid, formaldehyde, and formamide.
    Type: Grant
    Filed: January 20, 2014
    Date of Patent: February 12, 2019
    Assignee: SEKISUI CHEMICAL CO., LTD.
    Inventors: Masahiro Furutani, Akihiro Uenishi, Koichiro Iwasa
  • Patent number: 10197576
    Abstract: A method for the identification and localization of proteins or other biomolecules of a histologic tissue section comprises enzymatically digesting the biomolecules of two similar tissue sections while substantially preserving the biomolecule positions in the tissue sections. Next, a mass spectrometric image of the digest products in one of the tissue sections is acquired. Then, the digest products of the other tissue section are extracted and separated and the mass spectra and daughter ion spectra of all the digest products are acquired. A list of all identifiable biomolecules of the tissue section is created by comparing the mass spectra and daughter ion spectra with spectra in biomolecule structure databases or spectral libraries. Finally, the biomolecules in the list are assigned to digest products of the same mass in the mass spectra used to create the mass spectrometric image of the thin tissue section.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: February 5, 2019
    Inventors: Detlev Suckau, Martin Schürenberg, Rainer Paape, Christine Lübbert
  • Patent number: 10150806
    Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: December 11, 2018
    Assignee: The Regents of the University of California
    Inventors: Isaac S. Carrico, Brian L. Carlson, Peng Wu, Carolyn Ruth Bertozzi
  • Patent number: 10144938
    Abstract: A method of processing a solution comprising aromatic compounds. The method includes culturing a first microorganism in the solution for a time sufficient to reduce an amount of an aromatic compound and thereby generate a processed solution. The culturing may remove an aromatic compound deleterious to growth of a second microorganism without substantially reducing fermentable sugars, thereby permitting enhanced growth of the second microorganism in the processed solution. The culturing may additionally or alternatively convert an aromatic compound into a commodity chemical. The methods of the present invention are advantageous for processing lignocellulosic biomass for upgrading to biofuel or for generating commodity chemicals therefrom.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 4, 2018
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Daniel R. Noguera, Timothy J. Donohue, Julian Z. Oshlag, Weiping Zhang, Samantha L. Austin
  • Patent number: 10130654
    Abstract: The invention relates to a method of inducing osteogenesis in a subject comprising administrating a chitosan material to the a subject in need of osteogenesis, wherein the chitosan material having a chitosan with a degree of deacetylation at the range of 70%˜90%, and the chitosan is 0.15% by weight of the chitosan material. The method of the present invention can induce bone-forming and promote osseointegration around an implant.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: November 20, 2018
    Assignee: HANGLI BIOSCIENCES CO., LTD.
    Inventors: Yao Dung Hsieh, Earl Fu, Su Fang Kung, E-Chin Shen
  • Patent number: 10105322
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 23, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • Patent number: 10093887
    Abstract: The present invention provides methods for protein engineering and serine protease variants produced there from. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: October 9, 2018
    Assignee: DANISCO US INC.
    Inventors: Wolfgang Aehle, Luis G. Cascao-Pereira, David A. Estell, Frits Goedegebuur, James T. Kellis, Jr., Ayrookaran J. Poulose, Brian F. Schmidt
  • Patent number: 10081818
    Abstract: The present invention provides methods for producing cannabinoids and cannabinoid analogs as well as a system for producing these compounds. The inventive method is directed to contacting a compound according to Formula I or Formula II with a cannabinoid synthase. Also described is a system for producing cannabinoids and cannabinoid analogs by contacting a THCA synthase with a cannabinoid precursor and modifying at least one property of the reaction mixture to influence the quantity formed of a first cannabinoid relative to the quantity formed of a second cannabinoid.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: September 25, 2018
    Assignee: TEEWINOT TECHNOLOGIES LIMITED
    Inventors: Richard Peet, Malcolm J. Kavarana, Robert Winnicki, Marc Donsky, Mingyang Sun
  • Patent number: 10052415
    Abstract: The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cell.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 21, 2018
    Assignee: University of Utah Research Foundation
    Inventors: Dean Y. Li, Brent D. Wilson, Lise Sorensen Brunhart
  • Patent number: 10047134
    Abstract: The present disclosure relates to a comprehensive model for expression of recombinant peptides by Pichia pastoris. The model uses an easily controllable variable called ‘critical nutrient ratio’ for obtaining a right balance between product synthesis and it's degradation during the fermentation process. The extra cellular concentration of precursor could be increased by about 10 folds and the degradation constants could be reduced by about 10-20 folds for intracellular and extracellular cases respectively by controlling critical nutrient ratio and addition of soya flour hydrolysate and EDTA.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: August 14, 2018
    Assignee: Biocon Limited
    Inventors: Sanjay Tiwari, Gourav Awasthi, Gokul Jothiraman, Arun Chandavarkar
  • Patent number: 10018618
    Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: July 10, 2018
    Assignee: Peptide BioSciences, Inc.
    Inventor: Elliot Altman
  • Patent number: 10006059
    Abstract: The present invention utilizes yeast Candida tropicalis (NRRL 12968) for xylitol production, as an alternative and unexplored strain with high bioconversion rate and stability at higher initial xylose concentration. Different parameters are optimized for batch fermentation of xylose to xylitol such as initial xylose concentration, aeration (vvm), agitation (rpm), percent inoculum addition, and oxygen transfer rate. Maximum xylitol yield of 0.7 g/g of xylose is obtained with 3.33% inoculum, 250 g/l of initial xylose concentration, 0.2 vvm of aeration rate, and two stage agitation strategy comprising of 500 rpm for 0-24 hrs and 400 rpm for 24-72 hrs at not more than 72 hrs of fermentation time. The present invention coins a novel process mode of fermentation where the batch process is extended with continuous fermentation at optimum dilution rate of 0.02/hr with effective residence time of 52 hrs. Productivity of ‘batch followed by continuous’ process is 2.5 gm/lit/hr which is 1.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: June 26, 2018
    Assignee: PRIVI BIOTECHNOLOGIES PRIVATE LIMITED
    Inventors: Manish Petkar, Shweta Pawar, Arvind M. Lali
  • Patent number: 10000554
    Abstract: A modified laminin characterized in that a laminin or a heterotrimeric laminin fragment has a collagen binding molecule conjugated to at least one site selected from the ? chain N-terminus, the ? chain N-terminus and the ? chain N-terminus, and an extracellular-matrix material comprising the modified laminin, and collagen and/or gelatin serve as an alternative to Matrigel and are useful as an extracellular-matrix material for the formation of a safe three-dimensional tissue structure for regenerative medicine in humans.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: June 19, 2018
    Assignee: OSAKA UNIVERSITY
    Inventors: Kiyotoshi Sekiguchi, Shaoliang Li, Ryoko Sato
  • Patent number: 9951100
    Abstract: A method for separating and purifying recombinant human serum albumin (rHSA) from transgenic rice grain, sequentially comprising the steps of: 1) subjecting crude extract of rHSA to cation exchange chromatography to obtain primary product I; 2) subjecting the primary product I to anion exchange chromatography to obtain secondary product II; 3) subjecting the secondary product II to hydrophobic chromatography to obtain purified rHSA. The method may further comprise a step of ceramic hydroxyapatite chromatography prior to the hydrophobic chromatography. The method has the advantages of low cost and easy operation. The resultant rHSA has a purity of about 99% by HPLC.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: April 24, 2018
    Assignee: HEALTHGEN BIOTECHNOLOGY CO., LTD.
    Inventors: Daichang Yang, Yang He, Guangfei Li, Jingru Liu
  • Patent number: 8545459
    Abstract: A medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material. The fibrinolytic enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa).
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: October 1, 2013
    Assignee: Teleflex Medical Incorporated
    Inventors: Nisha Gupta, Joel Rosenblatt
  • Patent number: 8012739
    Abstract: This invention provides compositions and methods for generating components of protein biosynthetic machinery including orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases. Methods for identifying orthogonal pairs are also provided. These components can be used to incorporate unnatural amino acids into proteins in vivo.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: September 6, 2011
    Assignees: The Scripps Research Institute, The Regents of the University of California
    Inventors: Peter G. Schultz, Lei Wang, John Christopher Anderson, Jason W. Chin, David R. Liu, Thomas J. Magliery, Eric L. Meggers, Ryan Aaron Mehl, Miro Pastrnak, Stephen William Santoro, Zhiwen Zhang
  • Patent number: 7989216
    Abstract: An isolated polypeptide, Z domain, derived from B domain of Staphylococcal protein A, comprising a pair of anti-parallel alpha helices that are capable of binding a target, is provided herein. Introduction of different natural amino acid mutations in the polypeptide are provided here. Also provided are methods of using the two-helix binders.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: August 2, 2011
    Assignee: General Electric Company
    Inventors: Rong Zhang, Faisal Ahmed Syud, Jack Mathew Webster
  • Patent number: 7981691
    Abstract: An isolated polypeptide, Z domain, derived from B domain of Staphylococcal protein A, comprising a pair of anti-parallel alpha helices that are capable of binding a target, is provided herein. Introduction of a covalent bridge between two modified amino acids in the polypeptide is provided here. Also provided are methods of using the two-helix binders.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: July 19, 2011
    Assignee: General Electric Company
    Inventors: Joshua Kendall Hoerner, Rong Zhang, Faisal Ahmed Syud, Jack Mathew Webster
  • Patent number: 7977118
    Abstract: An isolated polypeptide, Z domain, derived from B domain of Staphylococcal protein A, comprising a pair of anti-parallel alpha helices that are capable of binding a target, is provided herein. Introduction of an un-natural amino acid in the polypeptide is provided here. Also provided are methods of using the two-helix binders.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: July 12, 2011
    Assignee: General Electric Company
    Inventors: Rong Zhang, Faisal Ahmed Syud, Jack Mathew Webster